Literature DB >> 6093442

Prognostic factors in testicular germ cell tumours. Experiences from 1058 consecutive cases.

M Vaeth, H P Schultz, H Von Der Maase, S A Engelholm, G Krag Jacobsen, B Nørgaard-Pedersen.   

Abstract

Prognostic factors in carcinoma of the testis were studied in 1058 adult patients treated in Denmark from 1976 to 1980. Separate analyses of the prognostic factors were carried out within the subgroups formed by a classification of the patients according to main histologic type (seminoma, non-seminoma) and the clinicoradiologic stage (I, II and III). The prognosis was measured by relapse-free survival (stage I and II), and survival (stage II and III). The prognostic value of 19 clinical and histologic parameters was evaluated using logrank tests and multiple regression analyses. An elevated HCG level and the size of retroperitoneal metastases were associated with a significantly adverse prognosis for seminoma in stage II. For non-seminomas the following parameters had a significant influence on the prognosis. Stage I: postoperative HCG level, local invasion and number of mitoses. Stage II: size of retroperitoneal metastases, postoperative HCG level, tumour size and local invasion. Stage III: presence of liver or lung metastases, postoperative HCG level, presence of choriocarcinoma or endodermal sinus tumour, and age.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6093442     DOI: 10.3109/02841868409136023

Source DB:  PubMed          Journal:  Acta Radiol Oncol        ISSN: 0349-652X


  2 in total

1.  Epidermal growth factor receptor is a marker for syncytiotrophoblastic cells in testicular germ cell tumors.

Authors:  Lukas Hechelhammer; Stephan Störkel; Bernhard Odermatt; Philipp U Heitz; Wolfram Jochum
Journal:  Virchows Arch       Date:  2003-06-03       Impact factor: 4.064

2.  The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours.

Authors:  T Powles; A Young; A Sanitt; A Sammit; J Stebbing; D Short; M Bower; P M Savage; M J Seckl; P Schmid
Journal:  Br J Cancer       Date:  2006-10-10       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.